Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Invested Capital (2016 - 2025)

Ani Pharmaceuticals' Invested Capital history spans 16 years, with the latest figure at $853.5 million for Q4 2025.

  • For Q4 2025, Invested Capital rose 17.46% year-over-year to $853.5 million; the TTM value through Dec 2025 reached $853.5 million, up 17.46%, while the annual FY2025 figure was $853.5 million, 17.46% up from the prior year.
  • Invested Capital for Q4 2025 was $853.5 million at Ani Pharmaceuticals, up from $822.7 million in the prior quarter.
  • Across five years, Invested Capital topped out at $853.5 million in Q4 2025 and bottomed at $199.7 million in Q4 2022.
  • The 5-year median for Invested Capital is $302.7 million (2021), against an average of $415.8 million.
  • The largest annual shift saw Invested Capital skyrocketed 27109.02% in 2021 before it crashed 70.97% in 2022.
  • A 5-year view of Invested Capital shows it stood at $687.8 million in 2021, then plummeted by 70.97% to $199.7 million in 2022, then skyrocketed by 51.65% to $302.9 million in 2023, then surged by 139.93% to $726.6 million in 2024, then increased by 17.46% to $853.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Invested Capital are $853.5 million (Q4 2025), $822.7 million (Q3 2025), and $242.0 million (Q2 2025).